Literature DB >> 19922966

Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men.

Seungho Ryu1, Yoosoo Chang, Hee-Yeon Woo, Sang-Ho Yoo, Nam-Kyong Choi, Won-Young Lee, Inah Kim, Jaechul Song.   

Abstract

In the absence of existing research, we examined the association between longitudinal changes in serum gamma-glutamyltransferase (GGT) levels and the risk for metabolic syndrome (MetS). A MetS-free cohort of 9148 healthy male workers, who had participated in a health checkup program in 2002, was followed until September 2007. Metabolic syndrome was defined according to the modified National Cholesterol Education Program, using body mass index instead of waist circumference. Standard Cox proportional hazards and time-dependent Cox models were performed. During 37 663.4 person-years of follow-up, 1056 men developed MetS. The risk of incident MetS increased across the baseline GGT quartiles, even after further updating GGT values during the follow-up. A longitudinal increase in GGT as a time-dependent variable as well as a non-time-dependent variable was significantly related to MetS after adjusting for age plus the elapsed time from visit 1 to visit 2, baseline MetS traits, uric acid, regular exercise, alcohol consumption, and smoking. Even within the GGT reference interval (<40 U/L), the fourth quartile of GGT change predicted the development of MetS (adjusted hazard risk, 1.61; 95% confidence interval, 1.26-2.07). Furthermore, these associations were consistently observed within the subgroups-those with body mass index less than 23 kg/m(2), C-reactive protein less than 3.0 mg/L, homeostasis model assessment of insulin resistance less than 2.04, alcohol intake not exceeding 20 g/d, alanine aminotransferase less than 35 U/L, an absence of ultrasonographically detected fatty liver, and an absence of any MetS traits. A longitudinal increase in the GGT level, even within the GGT reference interval, may be an independent predictor for MetS, regardless of the baseline GGT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922966     DOI: 10.1016/j.metabol.2009.08.024

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

1.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

2.  Relationship between serum gamma-glutamyltransferase levels and prehypertension in Chinese adults: the cardiometabolic risk in Chinese study.

Authors:  Yan Zhu; Ying Gong; Ruihua Zhu; Xue-Kui Liu; Yu-Ting Sun; Yu Wang; Lu Qi; Jun Liang
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-12       Impact factor: 3.738

Review 3.  Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis.

Authors:  Cun-Fei Liu; Yu-Ting Gu; Hai-Ya Wang; Ning-Yuan Fang
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons.

Authors:  Ryuichi Kawamoto; Yasuharu Tabara; Katsuhiko Kohara; Tetsuro Miki; Tomo Kusunoki; Shuzo Takayama; Masanori Abe; Tateaki Katoh; Nobuyuki Ohtsuka
Journal:  Cardiovasc Diabetol       Date:  2010-12-09       Impact factor: 9.951

5.  Association of Serum Gamma-Glutamyl Transferase and Ferritin with the Metabolic Syndrome.

Authors:  Dong Wei; Tao Chen; Jie Li; Yun Gao; Yan Ren; Xiangxun Zhang; Hongling Yu; Haoming Tian
Journal:  J Diabetes Res       Date:  2015-06-21       Impact factor: 4.011

6.  Hepatoprotective Effect of Silymarin (Silybum marianum) on Hepatotoxicity Induced by Acetaminophen in Spontaneously Hypertensive Rats.

Authors:  Abel Felipe Freitag; Gabriel Fernando Esteves Cardia; Bruno Ambrósio da Rocha; Rafael Pazzinatto Aguiar; Francielli Maria de Souza Silva-Comar; Ricardo Alexandre Spironello; Renata Grespan; Silvana Martins Caparroz-Assef; Ciomar Aparecida Bersani-Amado; Roberto Kenji Nakamura Cuman
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

7.  Serum gamma-glutamyltransferase is not associated with subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Hye Eun Yoon; Eun Young Mo; Seok Joon Shin; Sung Dae Moon; Je Ho Han; Eun Sook Kim
Journal:  Cardiovasc Diabetol       Date:  2016-08-05       Impact factor: 9.951

8.  Combinational risk factors of metabolic syndrome identified by fuzzy neural network analysis of health-check data.

Authors:  Yasunori Ushida; Ryuji Kato; Kosuke Niwa; Daisuke Tanimura; Hideo Izawa; Kenji Yasui; Tomokazu Takase; Yasuko Yoshida; Mitsuo Kawase; Tsutomu Yoshida; Toyoaki Murohara; Hiroyuki Honda
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-01       Impact factor: 2.796

9.  Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia.

Authors:  Nobuyuki Toshikuni; Atsushi Fukumura; Nobuhiko Hayashi; Tomoe Nomura; Mutsumi Tsuchishima; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  J Clin Biochem Nutr       Date:  2012-11-13       Impact factor: 3.114

10.  Elevated Serum Gamma-Glutamyltransferase (GGT) Activity and the Development of Chronic Kidney Disease (CKD) in Cigarette Smokers.

Authors:  Yuka Noborisaka; Masao Ishizaki; Michiko Yamazaki; Ryumon Honda; Yuichi Yamada
Journal:  Nephrourol Mon       Date:  2013-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.